# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
insitro, a pioneer in machine learning–driven drug discovery and development, and Bristol Myers Squibb (NYSE:BMY), today announ...
Bristol Myers Squibb (NYSE:BMY) today announced the presentation of data across its oncology portfolio and pipeline at the Euro...
SystImmune, Inc., a clinical-stage biotechnology company, today announced the treatment of the first patient in the IZABRIGHT-B...
Bristol Myers Squibb is acquiring Orbital Therapeutics for $1.5 billion, expanding its RNA and in vivo CAR T-cell therapy portf...
Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with po...
Health care stocks are rallying, but Pfizer, Merck and Bristol-Myers still trade below 10x forward P/E — a rare market discount.